Esperion Names Pharma CFO To Board
ANN ARBOR—Cholesterol-lowering drug developer Esperino Therapeutics Inc. has appointed Alan Fuhrman as a Class III director, with a term expiring at the 2022 meeting of stockholders. “On behalf of the Lipid Management team and our directors, I am very pleased to welcome Alan to the Esperion board. His extensive financial leadership experience will be extremely


